Laminin-R Antibody (33): sc-101518

Laminin-R Antibody (33) is a mouse monoclonal IgG2a light chain antibody that detects Laminin-R in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Laminin-R, also known as colon carcinoma laminin-binding protein, plays a crucial role in cell adhesion and migration, particularly in cancer progression. Anti-Laminin-R antibody (33) targets a protein primarily located in the cell membrane and integral to lysosomal membrane formation, allowing lysosomes to effectively attach to Laminin-coated surfaces. Laminin-R expression is significantly elevated in aggressive carcinomas, particularly in colon cancer, where levels are nine-fold higher compared to adjacent normal colonic epithelium. This upregulation indicates involvement in tumorigenesis and highlights potential as a biomarker for cancer diagnosis and prognosis. Laminin-R′s interaction with other extracellular matrix proteins, such as fibronectin and vitronectin, underscores importance in maintaining cellular architecture and facilitating cellular responses to the extracellular environment. Anti-Laminin-R antibody (33) serves as an essential tool for researchers investigating this protein′s role in cancer biology and potential as a therapeutic target.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Laminin-R Antibody (33) References:

1. Kruppel-like factors regulate the Lama1 gene encoding the laminin alpha1 chain.  |  Piccinni, SA., et al. 2004. J Biol Chem. 279: 9103-14. PMID: 14634001
2. Mutations in Lama1 disrupt retinal vascular development and inner limiting membrane formation.  |  Edwards, MM., et al. 2010. J Biol Chem. 285: 7697-711. PMID: 20048158
3. Lama1 mutations lead to vitreoretinal blood vessel formation, persistence of fetal vasculature, and epiretinal membrane formation in mice.  |  Edwards, MM., et al. 2011. BMC Dev Biol. 11: 60. PMID: 21999428
4. Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases.  |  Perry, JR., et al. 2012. PLoS Genet. 8: e1002741. PMID: 22693455
5. Mutations in LAMA1 cause cerebellar dysplasia and cysts with and without retinal dystrophy.  |  Aldinger, KA., et al. 2014. Am J Hum Genet. 95: 227-34. PMID: 25105227
6. Effect of a Single Nucleotide Polymorphism in the LAMA1 Promoter Region on Transcriptional Activity: Implication for Pathological Myopia.  |  Liang, Y., et al. 2016. Curr Eye Res. 41: 1379-1386. PMID: 26862816
7. Effects of High Glucose on the Expression of LAMA1 and Biological Behavior of Choroid Retinal Endothelial Cells.  |  Song, G., et al. 2018. J Diabetes Res. 2018: 7504614. PMID: 29967796
8. A mosaic intragenic microduplication of LAMA1 and a constitutional 18p11.32 microduplication in a patient with keratosis pilaris and intellectual disability.  |  Kashevarova, AA., et al. 2018. Am J Med Genet A. 176: 2395-2403. PMID: 30244536
9. Identification of a likely pathogenic structural variation in the LAMA1 gene by Bionano optical mapping.  |  Chen, M., et al. 2020. NPJ Genom Med. 5: 31. PMID: 33083009
10. Circular RNA hsa_circ_0000277 sequesters miR-4766-5p to upregulate LAMA1 and promote esophageal carcinoma progression.  |  Zhou, PL., et al. 2021. Cell Death Dis. 12: 676. PMID: 34226522

The preferred Laminin-R antibody is Laminin-R Antibody (H-2): sc-74515.